AXLRx Book a callCommission

Big Pharma · Company profile

Eli Lilly

Commission a Eli Lilly report

By therapy area

Therapy area All areas NeurologyImmunologyMetabolic

AXLRx reports featuring Eli Lilly

CI · Neurology · CI Team · Launch Lead US Alzheimer's Disease Competitive Intelligence Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate. US · In-Market · Read report → CI · Immunology · CI Team · Launch Lead US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. US · In-Market · Read report → CI · Metabolic · CI Team · Launch Lead US Obesity Competitive Intelligence Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality. US · In-Market · Read report → CI · Metabolic · CI Team · Launch Lead US Type 2 Diabetes Competitive Intelligence Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US Obesity Disease Landscape US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage. US · In-Market · Read report → CI · Immunology · CI Team · Launch Lead US Plaque Psoriasis Competitive Intelligence Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US, and the efficacy bar has moved from PASI 75 to PASI 90. IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2 all hold ground. US · In-Market · Read report →